Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.46 |
| ▸ | USP2 | O75604 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13319380 | 0.92 | USP2 (0.46) | CYP3A4USP2SMN1; SMN2PKMCYP2D6 | |
| SCHEMBL13319282 | 0.90 | CYP3A4 (0.51) | CYP3A4SMN1; SMN2CYP2D6MAPT | |
| SCHEMBL13319324 | 0.88 | CYP3A4 (0.47) | CYP3A4CYP2D6 | |
| SCHEMBL13319429 | 0.88 | CYP3A4 (0.49) | CYP3A4CYP2D6 | |
| SCHEMBL13319370 | 0.88 | HRH3 (0.46) | CYP3A4USP2SMN1; SMN2PKMCYP2D6 | |
| SCHEMBL13319357 | 0.88 | USP2 (0.45) | CYP3A4USP2SMN1; SMN2PKMMAPT | |
| SCHEMBL13319354 | 0.87 | CYP3A4 (0.48) | CYP3A4CYP2D6 | |
| SCHEMBL14095222 | 0.86 | USP2 (0.37) | CYP3A4USP2SMN1; SMN2PKMCYP2D6 | |
| SCHEMBL13319342 | 0.86 | USP2 (0.47) | CYP3A4USP2SMN1; SMN2PKMMAPT | |
| SCHEMBL13319399 | 0.86 | CYP3A4 (0.46) | CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144591-A1 | BENZIMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| US-20100144591-A1 | BENZIMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| EP-1499316-B1 | (1-4-PIPERIDINYL)BENZIMIDAZOLE DERIVATIVES USEFUL AS HISTAMINE H3 ANTAGONISTS | SCHERING CORP (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007075555-A2 | COMBINATION OF AN H3 ANTAGONIST/INVERSE AGONIST AND AN APPETITE SUPPRESSANT | SCHERING CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144591-A1 | BENZIMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GK, GCK | CYP3A4 339/4885USP2 4783/4885SMN1; SMN2 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.